Pazopanib Active in Patients with Anthracycline-Pretreated Metastatic Soft Tissue Sarcoma
Patients with metastatic soft tissue sarcoma who had previously received anthracycline had a threefold increase in progression-free survival when treated with pazopanib vs. placebo, according to results of the randomized Phase 3 PALETTE trial reported at American Society of Clinical Oncology’s 2011 Annual Meeting.